Drug Pipeline

EIK1001 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-21 NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy…		 Recruitment opened
2026-05-21 NCT07365319
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy…		 Trial sites expanded: 0 -> 3 locations
Active Studies by Phase
Phase 2/3
2
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT06697301 Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as… Advanced Melanoma Recruiting
NCT07365319 A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy… Non Small Cell Lung Cancer (Squamous or Non Squamous) Recruiting
Phase 2
NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With… NSCLC Active, Not Recruiting
Sponsors Running EIK1001 Trials
Eikon Therapeutics (3)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Melanoma (1) Lung Cancer (1)
Get alerts when EIK1001 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free